Trials / Completed
CompletedNCT00358930
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 501 |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-08-01
- Last updated
- 2009-04-28
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00358930. Inclusion in this directory is not an endorsement.